Can Immunotherapy Cause Chest Pain, and How Can You Cope?

Yes, chest pain can occur with cancer immunotherapy, and it is taken seriously because it may signal inflammation in the lungs (pneumonitis) or the heart (myocarditis or pericarditis). ^[1] Chest pain may also appear with shortness of breath, cough, or swelling, and it can arise during treatment or even weeks to months after starting therapy. ^[1] Some immune checkpoint inhibitors list chest pain as a warning sign of possible myocarditis that needs immediate medical attention. ^[2]

---

Why Chest Pain Happens with Immunotherapy

• Lung inflammation (pneumonitis): This can cause chest pain, new or worsening cough, and shortness of breath. ^[1] Pneumonitis is an immune-related side effect where the immune system inflames lung tissue. ^[1]
• Heart inflammation (myocarditis, pericarditis): Although uncommon overall, checkpoint inhibitors can inflame the heart muscle or its lining, leading to chest pain, palpitations, faintness, or breathlessness. ^[3] Immune-related cardiac problems can include myocarditis, heart rhythm disturbances, heart failure, and pericarditis. ^[4]
• Timing and risk: Myocarditis can start early often within the first few weeks of treatment and is more frequent and severe with combination immunotherapy. ^{[3] [5]}

---

Red Flags That Need Urgent Care

Seek emergency care right away if you have any of the following while on immunotherapy:

• Chest pain or pressure, especially if new, severe, or persistent. ^{[1] [2]}
• Shortness of breath, new/worsening cough, or low oxygen symptoms. ^[1]
• Fast or irregular heartbeat, dizziness, fainting, or swelling of legs. ^{[2] [5]}

These symptoms can indicate pneumonitis or myocarditis, which need urgent evaluation and treatment to prevent complications. ^{[1] [5]}

---

How Clinicians Evaluate Chest Pain During Immunotherapy

Your oncology team may use a combination of the following:

• Blood tests: Cardiac enzymes such as troponin and BNP/NT‑proBNP if cardiac toxicity is suspected; creatine kinase (CK) if myositis is also a concern; inflammatory markers (ESR/CRP) as indicated. ^{[6] [7] [8]}
• Imaging and heart testing: ECG, echocardiogram, and sometimes cardiac MRI; in select cases, endomyocardial biopsy. ^[5]
• Lung imaging: Chest X‑ray or CT to assess for pneumonitis. ^[1]

There is no clear evidence to support routine troponin testing for everyone on immunotherapy, but it is recommended when cardiac toxicity is suspected or in higher‑risk scenarios. ^{[9] [7]}

---

Evidence‑Based Treatment Approaches

• Hold immunotherapy while serious immune‑related side effects are being evaluated. ^[5]
• Start corticosteroids for suspected moderate to severe immune‑related inflammation (e.g., IV methylprednisolone for myocarditis), then taper as guided by response. ^[5]
• Escalate immunosuppression (e.g., IVIg, antithymocyte globulin, mycophenolate, or other agents) if severe myocarditis or if not responding to steroids; avoid infliximab in decompensated heart failure. ^{[5] [10]}
• Treat complications with guideline‑directed heart failure care when needed. ^[10]

Early recognition and treatment generally improve outcomes and help prevent organ damage. ^[5]

---

Practical Coping Tips for Users

While you must alert your oncology team about any chest pain, these steps can help while being evaluated:

• Do not ignore chest pain report it promptly to your care team, even if mild. ^[1]
• Limit exertion until you’re assessed; rest and avoid heavy activity that worsens pain or breathlessness. ^[1]
• Track symptoms (onset, severity, associated cough, shortness of breath, palpitations) to share with your team. ^[1]
• Use medicines only as advised by your oncology team; some over‑the‑counter pain relievers may not be appropriate if there is heart or lung inflammation. ^[5]
• Keep hydration and avoid triggers like smoking or environmental irritants that can worsen breathing discomfort. ^[1]

Most immune‑related side effects are manageable when treated early; serious problems can occur if they are not recognized and addressed quickly. ^[11]

---

When Chest Pain Might Be Less Concerning

Not all chest discomfort is dangerous for example, brief musculoskeletal pain from coughing or position changes can occur but there’s no reliable way to tell at home whether chest pain is benign or related to heart/lung inflammation from immunotherapy. ^[1] Because of this uncertainty, it’s safest to contact your team for guidance with any new chest pain. ^[1]

---

Key Takeaways

• Chest pain can be an immunotherapy side effect due to lung or heart inflammation, and it warrants prompt medical attention. ^[1]
• Early evaluation with labs and imaging helps identify pneumonitis or myocarditis and guides treatment. ^{[6] [5]}
• Management often includes holding therapy and corticosteroids, with escalation when needed. ^{[5] [10]}
• Act early report symptoms promptly to reduce the risk of serious complications. ^{[11] [1]}